Skip to main content

Lumakras

Pronunciation: loo-ma-krass
Generic name: sotorasib
Dosage form: oral tablets (120 mg, 240 mg, 320 mg)
Drug class: Miscellaneous antineoplastics

Medically reviewed by Carmen Pope, BPharm. Last updated on May 21, 2025.

What is Lumakras?

Lumakras is used to treat KRAS G12C-mutated non-small cell lung cancer (NSCLC) or colorectal cancer (CRC) in adults. It is an oral tablet that is taken once a day.

Lumakras’ mechanism involves targeting a specific cancer mutation called KRAS G12C that drives tumor growth. It works by permanently attaching to this mutated protein, locking it in an "off" position so it can't signal cancer cells to multiply. This stops tumor growth and causes cancer cell death, but only in cells with this specific mutation, sparing healthy cells. In some colorectal cancers, combining Lumakras with drugs that block EGFR (another cancer pathway) works better than either treatment alone. Lumakras is an inhibitor of the RAS GTPase family.

Lumakras (sotorasib) gained FDA approval on May 28, 2021. There is no generic

FDA approvals and indications

Lumakras is FDA approved to treat:

Your healthcare provider will perform a test to make sure that Lumakras is right for you.

It is not known if Lumakras is safe and effective in children.

Lumakras side effects

The most common side effects of Lumakras when used alone for NSCLC are:

The most common side effects of Lumakras when used in combination with panitumumab for CRC are:

Serious side effects and warnings

Lumakras may cause serious side effects, including:

Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with Lumakras if you develop side effects.

These are not all the possible side effects of Lumakras. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Amgen at 1-800-772-6436 (1-800-77-AMGEN).

Before taking

Before taking Lumakras, tell your healthcare provider about all your medical conditions, including if you:

How should I take Lumakras?

Take Lumakras exactly as your healthcare provider tells you to take it. Do not change your dose or stop taking this medicine unless your healthcare provider tells you to.

For colon or rectal cancer, you will also receive panitumumab through a vein in your arm (intravenously), given by your healthcare provider. You will first take Lumakras before you receive your first dose of panitumumab. Your healthcare provider will temporarily or permanently stop your treatment with panitumumab if your treatment with Lumakras is temporarily or permanently stopped.

If you cannot swallow Lumakras tablets whole:

If you take an antacid medicine, take Lumakras either 4 hours before or 10 hours after the antacid.

If you vomit after taking a dose of Lumakras, do not take an extra dose. Take your next dose at your regularly scheduled time the next day.

What happens if I miss a dose?

If you miss a dose of Lumakras, take the dose as soon as you remember. If it has been more than 6 hours, do not take the dose. Take your next dose at your regularly scheduled time the next day. Do not take 2 doses at the same time to make up for a missed dose.

What other drugs will affect Lumakras?

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, dietary, and herbal supplements. Lumakras can affect the way some other medicines work, and some other medicines can affect the way Lumakras works.

Especially tell your healthcare provider if you take antacid medicines, including Proton Pump Inhibitor (PPI) medicines or H2 blockers during treatment with Lumakras. Ask your healthcare provider if you are not sure.

Does Lumakras interact with my other drugs?

Enter medications to view a detailed interaction report using our Drug Interaction Checker.

How should I store Lumakras?

Store Lumakras at room temperature between 68°F to 77°F (20°C to 25°C).

What are the ingredients in Lumakras?

Active Ingredient: sotorasib

Inactive Ingredients: microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate. Tablet film coating material contains polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, iron oxide yellow and iron oxide red (320 mg tablet only).

Who makes Lumakras?

Lumakras is made by Amgen Inc., located in Thousand Oaks, CA 91320-1799 U.S.A.

Popular FAQ

How long do you take Lumakras for?

You will take Lumakras until your disease worsens or you have side effects that you cannot tolerate. Your doctor may be able to adjust your dose if you experience side effects like liver or lung toxicity, severe nausea or vomiting, severe diarrhea or other side effects. In some cases, you may need to stop treatment, as determined by your doctor.

Lumakras is approved by the FDA to treat non-small cell lung cancer (NSCLC) that has spread in the body or cannot be removed by surgery; or colon or rectal cancer (CRC) that has spread in the body. These tumors are characterized by an abnormal KRAS G12C gene. Your healthcare provider will perform a test to make sure that this treatment is right for you.

How effective is Lumakras, what's the survival rate?

In one clinical study with Lumakras, 45 out of 124 people (36%) saw their non-small cell lung cancer (NSCLC) tumors disappear or decrease in size by at least 30%. The median duration of response was 10 months. In another lung cancer study, the 12-month progression-free survival rate was 24.8% with Lumakras vs. 10.1% with the chemotherapy agent docetaxel. Continue reading

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.